Albireo Pharma (ALBO) Received its Third Buy in a Row
02 März 2022 - 05:05PM
TipRanks
After Wedbush and Jefferies gave Albireo Pharma (NASDAQ: ALBO) a
Buy rating last month, the company received another Buy, this time
from H.C. Wainwright. Analyst Ed Arce maintained a Buy rating on
Albireo Pharma today and set a price target of $80.00. The
company's shares closed last Wednesday at $26.88. According to
TipRanks.com, Arce is a 5-star analyst with an average return of
13.2% and a 39.6% success rate. Arce covers the Healthcare sector,
focusing on stocks such as Madrigal Pharmaceuticals, Aurinia
Pharmaceuticals, and Galmed Pharmaceuticals. Currently, the analyst
consensus on Albireo Pharma is a Strong Buy with an average price
target of $77.00, which is a 180.
https://www.tipranks.com/news/blurbs/albireo-pharma-albo-received-its-third-buy-in-a-row-5?utm_source=advfn.com&utm_medium=referral
Albireo Pharma (NASDAQ:ALBO)
Historical Stock Chart
Von Jul 2022 bis Aug 2022
Albireo Pharma (NASDAQ:ALBO)
Historical Stock Chart
Von Aug 2021 bis Aug 2022